In patients receiving immunotherapy, tumor cells can downregulate or alter the IFN-γ pathway, such as loss-of-function alleles in the gene encoding JAK1/2 and alterations in STAT1, to evade the effects of IFN-γ and thus develop resistance (36, 37). This evidence concerns the gene IFNG and neoplasm.